Table 4. .
Factors Associated With Liver Fibrosis Among HIV-Infected Females Patients Attending the AIDC and GPC Care Clinics in Urban and Rural Uganda (2015–2017)
| Urban Clinic | Rural Clinic | |||
|---|---|---|---|---|
| Explanatory variable | Adjusted Analysis | P Value | Adjusted Analysis | P Value |
| OR (95% CI) | OR (95% CI) | |||
| Age (10-y increase) | 1.3 (1.1–1.6) | .008 | 1.3 (1.0–1.6) | .052 |
| Ever used alcohol | 0.6 (0.4–0.9) | .016 | 0.6 (0.4–1.1) | .082 |
| Ever used tobacco | 1.5 (0.9–2.5) | .091 | 2.9 (1.5–5.9) | .003 |
| Ever used herbal medicine | 1.2 (0.7–1.9) | .474 | 1.0 (0.6–1.8) | .949 |
| Hepatitis B surface antigen positive | 1.1 (0.7–2.0) | .612 | 0.4 (0.1–1.1) | .072 |
| Hepatitis C antibody positive | 1.9 (0.6–6.0) | .263 | 2.2 (0.6–9.0) | .259 |
| On ART | - | - | 0.6 (0.1–4.9) | .594 |
| Detectable HIV viral load (≥1000 copies/mL) | 1.4 (0.6–3.3) | .403 | 1.4 (0.7–2.9) | .404 |
| Elevated liver transaminasesa | 2.3 (1.3–3.9) | .002 | 2.4 (1.1–5.3) | .028 |
Abbreviations: AIDC, Adult Infectious Diseases Clinic; ART, antiretroviral therapy; GPC, General Population Clinic; OR, odds ratio.
aAIDS Clinical Trials Group classification.